Cns Pharmaceuticals Company Insiders
| CNSP Stock | USD 3.71 0.09 2.49% |
Cns Pharmaceuticals employs about 3 people. The company is managed by 4 executives with a total tenure of roughly 7 years, averaging almost 1.0 years of service per executive, having 0.75 employees per reported executive. Discussion of Cns Pharmaceuticals' management performance can provide insight into the enterprise performance.
Cns |
Cns Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (2.24) % which means that it has lost $2.24 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1878) %, meaning that it created substantial loss on money invested by shareholders. Cns Pharmaceuticals' management efficiency ratios could be used to measure how well Cns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Cns Pharmaceuticals Workforce Comparison
Cns Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 165. Cns Pharmaceuticals claims roughly 3.0 in number of employees contributing just under 2% to equities under Health Care industry.
Cns Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cns Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cns Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cns Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cns Pharmaceuticals Notable Stakeholders
A Cns Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cns Pharmaceuticals often face trade-offs trying to please all of them. Cns Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cns Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| JD Esq | President CEO | Profile | |
| Waldemar Priebe | Founder | Profile | |
| Donald Picker | Chief Officer | Profile | |
| CPA CTP | Chief Officer | Profile |
About Cns Pharmaceuticals Management Performance
The success or failure of an entity such as Cns Pharmaceuticals often depends on how effective the management is. Cns Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cns management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cns management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company was incorporated in 2017 and is based in Houston, Texas. Cns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Cns Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Cns Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cns Pharmaceuticals within its industry.Cns Pharmaceuticals Manpower Efficiency
Return on Cns Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 6.3M | |
| Net Loss Per Executive | 4.7M |
Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.